Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers

Genetics in Medicine

Volumn 12, Issue 4 SUPPL., 2010, Pages

  Cook Deegan, Robert ^a   Derienzo, Christopher ^b   Carbone, Julia ^a   Chandrasekharan, Subhashini ^a   Heaney, Christopher ^a   Conover, Christopher ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APC; BRCA; Breast cancer; Colon cancer; Colorectal cancer; Familial adenomatous polyposis; FAP; Genetic testing; Intellectual property; Lynch syndrome; MSH; Myriad Genetics; Patents

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ADENOMATOUS POLYP; BREAST CANCER; CANCER GENETICS; CANCER SURGERY; CANCER SUSCEPTIBILITY; CANCER TEST; CLINICAL RESEARCH; COLON CANCER; CONTROLLED STUDY; DNA REPLICATION; FAMILIAL CANCER; GENETIC ANALYSIS; GOVERNMENT; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; LICENSING; MASTECTOMY; ONCOGENE; OVARIECTOMY; OVARY CANCER; REVIEW; RISK REDUCTION;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; GENES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEALTH SERVICES ACCESSIBILITY; HUMANS; LICENSURE, MEDICAL; MALE; OVARIAN NEOPLASMS; PATENTS AS TOPIC;

EID: 77951479651     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181d5a67b     Document Type: Review

References (122)

1. Rusconi W. Patenting and licensing of the breast cancer susceptibility genes\BRCA1 and BRCA2. Washington, DC: National Academies, 2005. Available at: http://www.genome.duke.edu/centers/cpg/documents/project1/clinical-genetic- testing/NAS%20Patents%20and%20BRCA%202-11-2005%20%282%29.pdf. Accessed November 18, 2009.
2. National Human Genome Research Institute. Breast cancer information core. Available at: http://research.nhgri.nih.gov/bic/. Accessed September 25, 2008.
3. Parthasarathy S. Architectures of genetic medicine: comparing genetic testing for breast cancer in the USA and UK. Soc Stud Med 2005;35:5-40. (Pubitemid 40427611)
4. Myriad Genetics, U.S. National Cancer Institute. Memorandum of understanding. Salt Lake, Utah: Myriad Genetics, 1999.
5. Lewin Group. The value of diagnostics: innovation, adoption, and diffusion into health care 2005. Falls Church, VA: Lewin Group, 2005.
6. Sevilla C, Julian-Reynier C, Eisinger F, et al. Impact of gene patents on the cost-effective delivery of health care: the case of BRCA1 genetic testing. Int J Technol Assess Health Care 2003;19:287-300. (Pubitemid 36818673)
7. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome relatives. Genet Med 2009;11:35-41.
8. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11:42-65.
9. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-1388.
10. Statement of Marc Grodman at stifling or stimulating\the role of gene patents in research and genetic testing. Washington, DC: House Judiciary Subcommittee on Courts, the Internet and Intellectual Property, 2007. Available at: http://judiciary.house.gov/hearings/pdf/Grodman071030.pdf. Accessed March 2, 2010.
11. Written statement of Wendy Chung at stifling or stimulating\the role of gene patents in research and genetic testing. Washington, DC: House Judiciary Subcommittee on Courts, the Internet and Intellectual Property, 2007. Available at: http://judiciary.house.gov/hearings/pdf/Grodman071030.pdf. Accessed March 2, 2010.
12. Judkins T, Hendrickson BC, Gonzales D, et al. Detection of large rearrangement mutations in BRCA1 and BRCA2 in 528 high risk families from North America by quantitative PCR based gene dose analysis. Paper presented at American Society of Human Genetics 54th Annual Meeting. Toronto, Canada, 2004. Available at: http://www.ashg.org/genetics/abstracts/abs04/f518.htm. Accessed July 11, 2008.
13. Hartmann C, John A, Klaes R, et al. Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum Mutat 2004;24:534.
14. Hendrickson B, Judkins T, Deffenbaugh A, Pyne K, Ward B, Scholl T. Recurrent intragenic rearrangement mutations in the tumor suppressor gene BRCA1: Prevalence results from 12,272 patients at high risk for breast and/or ovarian cancers and methods of biochemical analysis. Paper presented at 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, 2004.
15. Spence W, Judkins T, Schoenberger J, et al. Clinical testing experience for large genomic rearrangements in the BRCA1 and BRCA2 genes for hereditary breast and ovarian cancer. Paper presented at American Society for Human Genetics Meeting. San Diego, CA, October 23-27, 2007.
16. Harmon A. The DNA age: couples cull embryos to halt heritage of cancer. New York Times. September 3, 2006:A1.
17. van Orsouw N, Dhanda R, Elhaji Y, et al. A highly accurate, low cost test for BRCA1 mutations. J Med Genet 1999;36:747-753. (Pubitemid 29462318)
18. Genetic Technologies Limited. Further clarifications on BRCA testing. Public announcement for "personal use only." Available at: http://www.gtg. com.au/index.asp?menuid=060.070.130&artid= 10740&function=NewsArticle.Accessed November 8, 2008.
19. Parthasarathy S. Building genetic medicine: breast cancer, technology, and the comparative politics of health care. Cambridge: MIT Press, 2007.
20. Cho M, Illangasekare S, Weaver M, Leonard D, Merz J. Effects of patents and licenses on provision of clinical genetic testing services. J Mol Diagn 2003;5:3-8. (Pubitemid 36192993)
21. Holman CM. The impact of human gene patents on innovation and access: a survey of human gene patent litigation. UMKC Law Review 2007;76: 295-361.
22. Schoonmaker M, Bernhardt B, Holtzman N. Factors influencing health insurers' decisions to cover new genetic technologies. Int J Technol Assess Health Care 2000;16:178-189. (Pubitemid 30263212)
23. Lee S, Bernhardt B, Helzlsouer K. Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. Cancer 2002;94: 1876-1885. (Pubitemid 34241127)
24. Peterson E, Milliron K, Lewis K, Goold S, Merajver S. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002;11:79-87. (Pubitemid 34118316)
25. Agency for Healthcare Research. Genetic tests for cancer: technology assessment. Rockville, MD: Agency for Healthcare Research and Quality, January 9, 2006. Available at: http://www.ahrq.gov/clinic/ta/gentests/gentests.pdf. Accessed May 5, 2007.
26. American Cancer Society. Cancer facts and figures 2007. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWsecured.pdf. Accessed March 10, 2010.
27. American Cancer Society. Breast cancer facts and figures, 2005-2006. Available at: http://www.cancer.org/downloads/STT/CAFF2005BrF.pdf. Accessed March 10, 2010.
28. Agency for Healthcare Research and Quality. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: evidence synthesis 37. Rockville, MD: Agency for Healthcare Research and Quality, 2005.
29. Kaz A, Brentnall T. Genetic testing for colon cancer. Nat Clin Pract Gastroenterol Hepatol 2006;3:670-679. (Pubitemid 44824695)
30. McKusick VA. Entry 120435. Online Mendelia inheritance in man. Available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120435. Accessed January 19, 2009.
31. OncorMed. SEC EDGAR filing information: form 10-Q\quarterly report, June 30 1998. Gaithersburg, MD: OncorMed, 1998. Available at: http://www.sec.gov/ Archives/edgar/data/922821/0000950133-98-003049.txt. Accessed March 9 2010.
32. OncorMed. SEC EDGAR filing information: form 8-K\current report, July 07 1998. Gaithersburg, MD: OncorMed, 1998. Available at: http://www.sec.gov/ Archives/edgar/data/922821/0000950133-98-002539.txt. Accessed March 9 2010.
33. OncorMed. SEC EDGAR Filing Information: form 15-12B\securities registration termination September 30, 1998. Gaithersburg, MD: OncorMed, 1998. Available at: http://www.sec.gov/Archives/edgar/data/922821/0000936392-98- 001309.txt. Accessed March 9, 2010.
34. GoldER, Carbone J. Myriad Genetics: in the eye of the policy storm. Genet Med 2010;12(suppl):S39-S70.
35. Sevilla C, Moatti J, Julian-Reynier C, et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 2002;10:599-606. (Pubitemid 35277292)
36. Baylor College of Medicine Medical Genetics Laboratories. Prices and CPT codes. Available at: http://www.bcm.edu/geneticlabs/cptcodes.html. Accessed June 6, 2008.
37. Harvard Medical School. MLH1, MSH2, and MSH6 sequencing and deletion/duplication analysis for hereditary non-polyposis colorectal cancer (HNPCC) and HNPCC-like syndromes. Available at: http://www.hpcgg.org/LMM/ comment/HNPCC-info.jsp. Accessed June 20, 2008.
38. Harvard Medical School. APC gene sequencing and deletion/duplication analysis for familial adenomatous polyposis (FAP) and FAP-like syndromes. Available at: http://www.hpcgg.org/LMM/comment/APC-info.jsp. Accessed July 14, 2008.
39. United States Preventative Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Ann Intern Med 2005;143:355-361.
40. Bonis P, Trikalinos T, Chung M, et al. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evidence report/technology assessment No.150 prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022. Rockville, MD: Agency for Healthcare Research, May 2007. Available at: http://www.ahrq.gov/ downloads/pub/evidence/pdf/hnpcc/hnpcc.pdf Accessed June 4, 2008.
41. Levin B, Lieberman D, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-160. (Pubitemid 351830299)
42. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Colorectal Cancer Screening. V.1.2007.
43. Agency for Healthcare Research. U.S. Preventive Services Task Force: screening for breast cancer summary of recommendations 2002. Rockville, MD: Agency for Healthcare Research, 2002. Available at: http://www.ahrq.gov/clinic/ pocketgd09/gcp09s2.htm#BreastScreening. Accessed March 2, 2010.
44. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. (Pubitemid 46535708)
45. Agency for Healthcare Research. U.S. Preventive Services Task Force: screening for colorectal cancer summary of recommendations 2002. Rockville, MD: Agency for Healthcare Research, 2002.
46. Goldman NA, Restivo A, Goldberg GL. Screening and primary and secondary interventions for patients at high risk for ovarian cancer. Wom Oncol Rev 2003;3:269-274. (Pubitemid 38088444)
47. Higashi M, Veenstra D. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am JManag Care 2003;9:493-500. (Pubitemid 36949536)
48. Carroll A, Downs S. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 2006;117(5 Pt 2):S287-S295. (Pubitemid 46071316)
49. Cutler DM, Landrum MB, Stewart KA. Intensive medical care and cardiovascular disease disability reductions. Cambridge, MA: National Bureau of Economic Research, May 2006.
50. Murphy KM, Topel RH. The economic value of medical research. Measuring the gains from medical research: an economic approach. Chicago: University of Chicago Press, 2003:41-73.
51. Saam J, Burbidge L, Bowles K, et al. Decline in rate of BRCA1/2 variants of uncertain significance: 2002-2008. Paper presented at National Society of Genetic Counselors Annual Meeting. Los Angeles, CA, 2008.
52. Agency for Healthcare Research. U.S. Preventive Services Task Force: chemoprevention: breast cancer. Rockville, MD: Agency for Healthcare Research, July 2002 http://www.ahrq.gov/clinic/uspstf/uspsbrpv.htm. Accessed March 9 2010.
53. Anderson K, Jacobson J, Heitjan D, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006;144:297-407. (Pubitemid 46768161)
54. American Gastroenterological Association. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001;121: 198-213. (Pubitemid 32591530)
55. Vasen H, Wijnen J, Menko F, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-1027. (Pubitemid 26113739)
56. Syngal S, Weeks J, Schrag D, Garber J, Kuntz K. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998;192:787-796. (Pubitemid 28522813)
57. Church J, Simmang C, Standards Task Force, American Society of Colon and Rectal Surgeons, Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of The American Society of Colon and Rectal Surgeons. Parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003; 46:1001-1012.
58. Merz J. Disease gene patents: overcoming unethical constraints on clinical laboratory medicine. Clin Chem 1999;45:324-330.
59. Doheny K. Genetic tests for cancer not perfect. HealthDay. March 21, 2006.
60. Myriad Genetics. Clinical update: testing for hereditary breast and ovarian cancer syndrome. Available at: http://www.myriadtests.com/provider/doc/ clinical.update.v4n05.pdf. Accessed November 18, 2009.
61. MRC Holland. SALSA MLPA Kit P002-B1 BRCA1 specification sheet. Amsterdam: MRC Holland, 2008.
62. Myriad Genetics Laboratories. BRACAnalysis® technical specifications. Available at: http://www.myriadtests.com/provider/doc/tech-specs-brac. pdf Accessed December 19, 2007.
63. Page D. FDA approves study for breast cancer risk test by InterGenetics. Journal Record. September 20, 2006.
64. First genetic-based breast cancer risk test available in the U.K. and Ireland. Genetic Engineering and Biotechnology News. March 1, 2007. Available at: http://www.genengnews.com/news/bnitem.aspx?name=13573820. Accessed March 9, 2010.
65. Phillips K, Veenstra D, Ramsey S, Van Bebber S, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact of healthcare delivery and costs. Am J Manag Care 2004;10:425-432.
66. Myriad Genetics. Myriad reimbursement assistance program. Available at: http://myriadtests.com/mrap.htm. Accessed July 12, 2008.
67. InterGenetics builds DNA analysis and genotyping laboratory; laboratory essential to commercialization of nation's first genetic-based breast cancer risk predictive test applicable to all women. Business Wire. September 7, 2005. Available at: http://findarticles.com/p/articles/mi-m0EIN/is-2005-Sept-7/ai- n15346276/. Accessed March 9, 2010.
68. Winnick E. Perlegen eyes first-half 2009 launch of breast cancer Dx panel. GenomeWeb News. September 25, 2008.
69. Pinker S. My genome, my self. New York Times Magazine. January 7, 2009. Available at: http://www.nytimes.com/2009/01/11/magazine/11Genome-t. html?-r=2&scp=1&sq=pinker&st=cse. Accessed January 21, 2009.
70. O'Connor M. Genetic technologies and breast cancer. Courier-Mail. October 27, 2008.
71. Shanahan L. Call to act on breast cancer test. The Age. October 28, 2008.
72. Macey J. Company seeks to monopolise breast cancer test. ABC News Radio: The World Today. October 23, 2008. Available at: http://www.abc.net.au/news/ stories/2008/10/23/2399406.htm?site=news. Accessed March 3, 2010.
73. Genetic Technologies to enforce BRCA test rights in Australia, New Zealand. GenomeWeb Daily News. July 21, 2008.
74. Cresswell A. A price on your genes. The Australian. July 30, 2008.
75. Macey J. Consumer watchdog investigates gene company. The World Today. October 23, 2008. Available at: http://www.abc.net.au/worldtoday/content/2008/ s2399139.htm. Accessed November 8, 2008.
76. Examination of budget estimates 2008-2009. Additional information received. Health and ageing portfolio. Community Affairs Committee, December 3, 2008.
77. Transcript of Senate Standing Committee on Community Affairs Estimates. Community Affairs Committee, October 22 2008.
78. Genetic Technologies Limited. Intention to appoint a director http://www.gtglabs.com.au/announcements/intention-to-appoint-a-director. Accessed March 10 2010.
79. Caulfield T, Gold ER. Genetic testing, ethical concerns, and the role of patent law. Clin Genet 2000;57:370-375.
80. Centers for Disease Control and Prevention. Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing\Atlanta, Denver, Raleigh-Durham, and Seattle 2003. MMWR Morbid Mort Wkly Rep 2004; 53:603-606.
81. Mouchawar J, Hensley-Alford S, Laurion S, et al. Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally occurring experiment. Genet Med 2006;7:191-197.
82. Mouchawar J, Laurion S, RitzwollerD, Ellis J, Kulchak-Rahm A, Hensley-Alford S. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization. Am J Manag Care 2005;11:601-608.
83. Schwartz M, Lerman C, Brogan B, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14:1003-1007.
84. Myriad Genetics. Myriad Genetics launches awareness advertising campaign to educate women about hereditary risks of breast and ovarian cancers. Available at: http://investor.myriad.com/releasedetail.cfm?ReleaseID=325769. Accessed March 10, 2010.
85. Myriad Genetics. Myriad Genetics reports results for third quarter of fiscal 2008. Available at: http://investor.myriad.com/releasedetail.cfm? ReleaseID=325474. Accessed November 15, 2009.
86. Shappell HL, Matloff ET. Writing effective insurance justification letters for cancer genetic testing: a streamlined approach. J Genet Couns 2001; 10:331-341.
87. Kieran S, Loescher L, Lim K. The role of financial factors in acceptance of clinical BRCA genetic testing. Genet Test 2007;11:101-110.
88. Economic Research Initiative of the Uninsured. Table 2\CPS adult population (age 19-64) calendar year 2005. Available at: http://www.rwjf-eriu. org/fastfacts/cps2005-2.html. Accessed January 11, 2010.
89. Kuerer H, Hwang E, Anthony J, et al. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol 2000;7:325-332.
90. Kauff N, Scheuer L, Robson M, et al. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 2001;3:422-425.
91. Liu S, Chollet D. Price and income elasticity of the demand for health insurance and health care services: a critical review of the literature. Cambridge, MA: Mathematica Policy Research, March 26 2006. Available at: http://www.mathematica-mpr.com/publications/pdfs/priceincome.pdf. Accessed March 9, 2010.
92. NCBI Sequence Viewer. Homo sapiens breast cancer 1. Available at: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NG-005905.1&from= 10511&to=91665&dopt=gb. Accessed June 1, 2007.
93. NCBI Sequence Viewer. Homo sapiens chromosome 13, reference assembly. Available at: http://www.ncbi.nlmnih.gov/entrez/viewer.fcgi?val=NC-000013. 9&from=31787617&to=31871809&dopt=gb. Accessed June 1,2007.
94. NCBI Sequence Viewer. Homo sapiens chromosome 5, reference assembly. Available at: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NC- 000005.8&from=112101483&to=112209835&dopt=gb. Accessed March 3, 2010.
95. NCBI Sequence Viewer. Homo sapiens chromosome 3, reference assembly. Available at: http://www.ncbi.nlmnih.gov/entrez/viewer.fcgi?val=NC-000002. 10&from=47483767&to=47563864&dopt=gb. Accessed March 3, 2010.
96. NCBI Sequence Viewer. Homo sapiens chromosome 2, reference assembly. Available at: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NC-000002. 10&from=47863790&to=47887596&dopt=gb. Accessed March 3, 2010.
97. Grann V, Jacobson J, Whang W, et al. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am 2000;6:13-20.
98. Hershman D, Sundararajan V, Jacobson J, Heitjan D, Neugut A, Grann V. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 2002;20:9-16.
99. Eckermann S, Martin A, Stockler M, Simes R. The benefits and costs of tamoxifen for breast cancer prevention. Aust N Z J Public Health 2003; 27:34-40.
100. Grann V, Panageas K, Whang W, Antman K, Neugut A. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998;16:979-985.
101. Tengs T, Berry D. The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Dis Manag Clin Outcome 2000;1:15-24.
102. National Cancer Institute. Learning about colon cancer. Available at: http://www.genome.gov/10000466. Accessed February 1, 2007.
103. Centers for Disease Control. Colorectal cancer test use among persons aged 50 years\United States 2001. MMWR Morbid Mort Wkly Rep 2003; 52:193-196.
104. Plaintiffs' Complaint. Association for Molecular Pathology, et al., v. United States Patent and Trademark Office, et al. Civil Action No. 09-4515 (RWS), Southern District of New York (S.D.N.Y.), filed May 12, 2009.
105. Defendant United States Patent and Trademark Office's Memorandum of Law in Support of Motion to Dismiss. Association for Molecular Pathology, et al., v. United States Patent and Trademark Office, et al. Civil Action No. 09-4515 (RWS), S.D.N.Y., filed July 13, 2009.
106. Memorandum of Law in Support of Defendants' Motion to Dismiss. Association for Molecular Pathology, et al., v. United States Patent and Trademark Office, et al. Civil Action No. 09-4515 (RWS), S.D.N.Y. filed July 13
107. Plaintiffs' Memorandum of Law in Support of Motion to Conduct Jurisdictional Discovery. Association for Molecular Pathology, et al., v. United States Patent and Trademark Office, et al., Civil Action No. 09-4515 (RWS), S.D.N.Y., filed August 26, 2009.
108. Plaintiffs' Memorandum of Law in Support of Motion for Summary Judgment. Association for Molecular Pathology, et al., v. United States Patent and Trademark Office, et al., Civil Action No. 09-4515 (RWS), S.D.N.Y., filed August 26, 2009.
109. Order to Deny Defendants' Motion to Dismiss. Association for Molecular Pathology, et al., v. United States Patent and Trademark Office, et al., Civil Action No. 09-4515 (RWS), S.D.N.Y., filed November 1, 2009.
110. European Patent Office Board of Appeals. Decision of the Technical Board of Appeal 3.3.04 of 13 November 2008, Case No. T 0666/05-3.3.04. European Patent Office Board of Appeals, 2008.
111. New European Patent Specification, EP 0 705 903 B2.
112. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869-2876.
113. Pereira LHM, Pineda MA, Rowe WH, et al. The BRCA1 Askhenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. BMC Genet 2007;8:68.
114. Zimmeren EV, Requena G. Ex-officio licensing in the medical sector: the French model. In: van Overwalle G, editor. Gene patents and public health. Brussel: Bruylant, 2007:123-147.
115. Overwalle GV. The Belgian compulsory license for public health [translation and summary of Debrulle J, De Cort L, Petit M. La licence obligatoire belge pour raisons de sante publique]. In: van Overwalle G, editor. Gene patents and public health. Brussel: Bruylant, 2007:199-209.
116. Article 21, Council of the European Union Working Document 13706/09 http://register.consilium.europa.eu/pdf/en/09/st13/st13706.en09.pdf. Accessed October 20 2009.
117. Genetic Technologies Limited. New position re BRCA testing http://www.gtglabs.com.au/announcements/new-position-re-brca-testing. Accessed March 10 2010.
118. Genetic Technologies Limited (GTG)\ASX listed company information fact sheet. Available at: http://www.asx.com.au/asx/research/companyInfo. do?by=asxCode&asxCode=GTG. Accessed October 20, 2009.
119. Senate Community Affairs Committee inquiry into gene patents: terms of reference. Available at: http://www.aph.gov.au/senate/committee/clac-ctte/gene- patents/tor.pdf. Accessed October 20, 2009.
120. Inquiry into gene patents\public hearings and transcripts. Available at: http://www.aph.gov.au/senate/committee/clac-ctte/gene-patents/hearings/index. htm. Accessed October 20, 2009
121. Commonwealth of Australia Parliamentary Debates. Senate Community Affairs References Committee: gene patents. Canberra: Commonwealth of Australia Parliamentary Debates, 2009.
122. Dayton L. Patently tricky dispute drags on: who owns your genes. The Australian. December 12, 2009.